{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T14:27:42Z","timestamp":1784125662839,"version":"3.55.0"},"reference-count":48,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2020,10,22]],"date-time":"2020-10-22T00:00:00Z","timestamp":1603324800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100008519","name":"University of Arkansas for Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008519","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>Two promising epigenetic therapeutic targets have emerged for the treatment of hematologic malignancies, BET and CBP\/EP300 proteins. Several studies have shown that targeting these individual classes of proteins has anti\u2010tumor activity in multiple myeloma (MM), as well as other cancers. Here, we present the first data exploring the anti\u2010tumor activity of two novel dual inhibitors, NEO2734 and NEO1132, of both BET and CBP\/EP300 proteins in MM.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Sixteen MM cell lines (MMCLs) were treated with the dual inhibitors NEO2734 and NEO1132, the single BET inhibitors JQ1, OTX015, IBET\u2010762, and IBET\u2010151, and a single CBP\/EP300 inhibitor CPI\u2010637.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The dual inhibitor NEO2734 showed strong anti\u2010tumor activity and was consistently highly active against all MMCLs, being as potent as JQ1 and more so than other single inhibitors. NEO2734 and NEO11132 induced a significant G1 cell cycle arrest and decreased c\u2010MYC and IRF4 protein levels in MMCLs compared to the other single inhibitors. Sensitivity to the dual inhibitors was not dependent on a specific MM molecular subgroup but correlated with c\u2010MYC protein expression levels.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The dual inhibition of BET and CBP\/EP300 has potential therapeutic benefits for patients with MM.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ejh.13525","type":"journal-article","created":{"date-parts":[[2020,9,30]],"date-time":"2020-09-30T15:14:58Z","timestamp":1601478898000},"page":"90-99","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Targeting both BET and CBP\/EP300 proteins with the novel dual inhibitors NEO2734 and NEO1132 leads to anti\u2010tumor activity in multiple myeloma"],"prefix":"10.1111","volume":"106","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0488-5603","authenticated-orcid":false,"given":"Katie R.","family":"Ryan","sequence":"first","affiliation":[{"name":"UAMS Myeloma Center Little Rock AR USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Giles","sequence":"additional","affiliation":[{"name":"Developmental Therapeutics Consortium Chicago IL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gareth J.","family":"Morgan","sequence":"additional","affiliation":[{"name":"UAMS Myeloma Center Little Rock AR USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,10,22]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1011442"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-016-0282-1"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2016.122"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3257"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/305443a0"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2007.07.003"},{"issue":"17","key":"e_1_2_9_8_1","first-page":"4701","article-title":"Altered expression of growth\u2010regulated protooncogenes in human malignant plasma cells","volume":"49","author":"Palumbo AP","year":"1989","journal-title":"Cancer Res."},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature07064"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2014.13"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.2114"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4286"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2014.29"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature09504"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature09589"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature10334"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-01-478420"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2011.08.017"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M707603200"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.01020-07"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1108190108"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.164632"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-0098"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41589-019-0264-z"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)82001-2"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2016.06.013"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.10744"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature09730"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2396"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-012-1254-4"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41401-019-0237-5"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.10483"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-019-0173-0"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.53"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-08-445262"},{"issue":"4","key":"e_1_2_9_36_1","first-page":"477","article-title":"Established immunoglobulin producing myeloma (IgE) and lymphoblastoid (IgG) cell lines from an IgE myeloma patient","volume":"7","author":"Nilsson K","year":"1970","journal-title":"Clin Exp Immunol"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910510121"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001879"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2018.11.006"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2016.03.013"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201910659"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-20-0087"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.97.1.228"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.19.1916"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0000000000000389"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0689-1"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-0605"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.4214"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.106"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.13525","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ejh.13525","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.13525","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T10:33:03Z","timestamp":1693823583000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.13525"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,22]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["10.1111\/ejh.13525"],"URL":"https:\/\/doi.org\/10.1111\/ejh.13525","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,22]]},"assertion":[{"value":"2020-08-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-23","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}